To determine if universal Group B Streptococcus (GBS) culturing and antibiotic prophylaxis of obstetric patients decreased the incidence of neonatal early-onset GBS sepsis and mortality and maternal chorioamnionitis.
Since the landmark studies by Boyer and associates in the 1980s demonstrated the benefit of prenatal Group B streptococcal (GBS) culturing and intrapartum antibiotic prophylaxis for parturients considered at increased risk, much attention has been focused on GBS, as a pathogen in early neonatal sepsis. 1, 2 There is a 20% to 30% colonization rate for GBS in the maternal population of this country, 3 ,4 yet overall early-onset neonatal GBS sepsis rates are less than 3/1000 deliveries. 5, 6 Maternal GBS colonization was shown to increase the risk for neonatal sepsis in the setting of preterm delivery (PTD), preterm premature rupture of membranes (PPROM), prolonged rupture of membranes (PROM), chorioamnionitis, or in the event of a previous child affected with GBS sepsis. 1 A recent meta-analysis suggested that a 30-fold beneficial effect of prophylactic penicillin in labor in preventing neonatal GBS sepsis is equally beneficial in GBS-colonized women with or without prenatal risk factors. 7 However, Ohlsson and Myhr, 8 in a critical review of all randomized controlled trials regarding intrapartum chemoprophylaxis for GSB sepsis, challenged whether a reduction in proven neonatal sepsis has been conclusively demonstrated. Maternal risks of chorioamnionitis and endometritis have also been reported to be increased in those with GBS colonization. 9 Until recent guidelines regarding GBS surveillance were published by the Centers for Disease Control and Prevention (CDC) 10 in conjunction with the American College of Obstetrics and Gynecology 11 and the American Academy of Pediatrics, 12 maternal-fetal medicine specialists and neonatologists in this country were managing gravidas and neonates in a very non-uniform manner. 13 Few issues in obstetrics have evoked such controversy as that of GBS screening and prophylaxis. In 1994 we initiated a policy that included systematic prenatal universal culturing at 28 weeks' gestation followed by antibiotic prophylaxis in labor for all positive culture, and for all the above detailed risk factors. We set forth to investigate whether this policy resulted in a decrease in the incidence of early-onset GBS sepsis and mortality in our population, which was previously prophylaxed only sporadically at the discretion of the attending obstetrician.
Original Article
STUDY DESIGN
An observational time series study was performed on two cohorts over 8 years at the University of Chicago, January 1, 1989, through December 31, 1996. We included all mothers and their infants delivering at our hospital during these years and divided them into two groups: before January 1, 1994, when there was no GBS surveillance policy in effect, and after January 1, 1994, when a formal GBS universal culturing and antibiotic prophylaxis policy was instituted.
Mothers
Before January 1994, mothers were prophylaxed sporadically in labor against GBS sepsis, only if the attending obstetrician deemed it appropriate. If antibiotics were used, they were given empirically-the factor for which most mothers received prophylaxis was chorioamnionitis, whereas antibiotic use for PPROM, PROM, and PTD was highly variable, according to the opinion of the attending obstetrician during the month of the obstetric service. Cultures were commonly performed for GBS when patients were admitted to the hospital with the diagnosis of preterm labor or PPROM, but antibiotic treatment or prophylaxis of these patients for positive cultures was very inconsistent. In this cohort there were 15,620 deliveries during the 5 years.
For the second time period of 3 years (1994 through 1996), with 8748 deliveries occurring, a uniform GBS policy had been instituted at the University of Chicago. Universal GBS culturing at 28 weeks' gestation was to be performed, and all mothers who were GBS-positive were to receive prophylactic antibiotics in labor as well as those mothers with the following risk factors when they, too, were in labor: expected PTD of Ͻ37 weeks' gestation, PPROM of Ͻ37 weeks, PROM of Ͼ18 hours, a previous child affected by symptomatic GBS infection, and maternal fever in labor of Ͼ37.8°C. GBS testing was performed by swabbing the rectovaginal area with microorganism collection swabs and transported to the laboratory in transport media (Amies; Starplex Scientific, Ontario, Canada). All cultures were plated on BBL trypticase soy with 5% sheep blood agar or BBL colistin, nalidixic acid agar with 5% sheep blood. The samples were incubated in CO 2 for 24 to 72 hours at 35 to 37°C in the microbiology laboratory at the University of Chicago and read according to standard protocol.
At the time of labor, for those requiring antibiotics, ampicillin was used for prophylaxis, 2 gm intravenously every 6 hours until delivery. Clindamycin, 600 mg intravenously every 6 hours, was substituted if the patient had a penicillin allergy. If patients did not receive the antibiotics for at least 4 hours before delivery, they were considered as not having received appropriate antibiotic prophylaxis for the purposes of this study. This is based on the original study design by Boyer, 1 who demonstrated the effect of prophylactic antibiotics.
Chorioamnionitis was defined as intrapartum maternal temperature Ͼ 37.8°C and two or more of the following conditions: maternal tachycardia Ͼ 100 beats per minute, fetal tachycardia Ͼ 160 beats per minute, uterine tenderness, foul odor of the amniotic fluid, or maternal leukocytosis Ͼ 15,000 cells/mm 3 .
14 To assess compliance with the GBS policy instituted in January 1994, we used a computer-generated randomly-selected list of 100 patients who had delivered in the latter time period and retrieved their medical records chart for detailed review. We assessed compliance with the culturing protocol, reasons for failed culturing, and the GBS colonization rate.
Infants 25,402 infants delivered at the University of Chicago during the entire study period from January 1, 1989 through December 31, 1996, with 16,272 births occurring in the first time period, and 9130 infants delivering in the latter. Infants were diagnosed with early-onset GBS sepsis if their blood or spinal fluid cultures became positive for GBS within the first 7 days of life. Infants with positive cultures were identified by searching the microbiology computer database, which stores all culture results and generates reports. Any infant born to a mother with the previously defined risk factors, or with signs of sepsis on admission to, or during the stay in the nursery, had blood cultures drawn. Signs of sepsis prompting such cultures included seizures, respiratory distress, fever, hypoglycemia, temperature instability, hypotension, or feeding intolerance. Spinal fluid cultures were performed in the setting of lethargy, poor feeding, seizures, or whenever a positive blood culture result was obtained. Protocols for treatment of neonates in the intensive care unit and general nursery were similar over the two time periods with no change in management of sepsis based on the initiation of our study. A detailed medical records chart review was performed for all infants born at the University of Chicago with positive blood or spinal fluid cultures for GBS during both study periods.
Analysis
Predictor variables for this study were GBS culturing and antibiotic usage. Outcome variables included the incidence of GBS sepsis and mortality in the neonates as well as the maternal chorioamnionitis rate. Chorioamnionitis was studied to evaluate the change in this variable in light of the increased use of antibiotics in our patient population. Two-tailed -squared and Fisher exact tests were used for analysis, and p Ͻ 0.05 was considered significant.
RESULTS
The University of Chicago is an urban tertiary center serving a population that is predominantly African American and indigent. Over half of our patients are financially dependent on public aid, while one fifth of the patients delivering at our center are unregistered, receiving no prenatal care. All these patients are cared for by the resident obstetrics service under the direct supervision of a maternal-fetal medicine attending physician. The remaining patients are insured and managed by their private obstetrician. The two cohorts were not demographically different in age, race, parity, or ratio of private/service patients.
The computer-generated random review of 100 patient's charts during the second study period revealed that 72% of patients were enrolled for prenatal care at our institution, whereas 28% were unregistered and had no prenatal care with our institution, and no information regarding GBS status was available. Only 40 of the 100 reviewed patients (56% of our registered antenatal patients) were cultured according to protocol. The 32 of 100 reviewed patients (44% of registered patients) in whom culturing did not occur were found to have been missed secondary to patient noncompliance with prenatal visits (70%), preterm delivery before 28 weeks (20%), and physician error (10%). The maternal GBS colonization rate among those cultured at our center was 26%. Early-onset GBS sepsis was diagnosed in 35 of the 16,272 infants delivered in the first time period, whereas 20 of the 9130 neonates born after universal culturing was instituted in the second time period were found to suffer early-onset GBS sepsis. Interestingly, all infants with early-onset GBS sepsis developed positive cultures from samples taken during the first or second day of life. All other positive GBS cultures arose in infants with late-onset GBS sepsis, with cultures positive on the 11th to 47th days of life and were not considered further in this study. The two early-onset GBS septic infants who had positive spinal fluid cultures also had positive blood cultures for GBS. Table 1 summarizes the early-onset GBS pathology, use of antibiotics, and chorioamnionitis in the two time periods. With the new policy in the latter time period, the use of intrapartum antibiotics doubled, but we were unable to detect a significant change in the incidence of early-onset GBS sepsis. The case fatality rate for earlyonset GBS sepsis declined, but this change was not significant. The overall rate of GBS mortality did not change significantly either between the two cohorts. Figure 1 illustrates the yearly cases of earlyonset GBS sepsis and case fatalities.
In the earlier time period, before universal culturing, 60% of gestations with early-onset GBS sepsis had risk factors for the disease, but only one quarter of these mothers received antibiotic prophylaxis (15% of the total early-onset GBS septic infants) (Figure 2A ). After the universal culturing policy began, a similar number, 55% of the neonates with early-onset GBS sepsis, were noted to have risk factors, but only 45.5% of this group received antibiotic prophylaxis (30% of the total early-onset GBS septic infants) according to protocol ( Figure  2B ). The percentage of infants with early-onset GBS sepsis that had no maternal risk factors, and therefore did not receive prophylactic antibiotics, did not change over the two time periods (40% and 45%, respectively). Early-onset GBS sepsis mortalities, all occurring in the earlier study period, are detailed in Table 2 .
DISCUSSION
Despite a universal GBS culturing policy and liberal use of antibiotics in labor, we were unable to effect a change in the rate of early-onset GBS sepsis at our inner-city tertiary center. Even although the decrease in early-onset GBS sepsis mortality from 14.3% to 0% is striking, it is not statistically significant. During the latter GBS policy surveillance period, our maternal antibiotic use in labor doubled and, as would be expected, the chorioamnionitis rate decreased. Our results emphasize the major obstacles encountered in attempting to effectively carry out a GBS surveillance policy at our center: compliance issues related to our population and the nature of a university-based tertiary inner-city hospital.
However, use of antepartum GBS culturing and antibiotic prophylaxis for all positive cultures, on the contrary, has been shown to be an effective means of decreasing early-onset GBS disease in neonates in several reports. [15] [16] [17] Universal culturing and prophylactic ampicillin in labor for all positive cultures was used at the University of North Carolina, with 98% compliance in performing the cultures, a carriage rate of only 14%, and complete elimination of GBS sepsis in their population. 17 This center differs from our population in that only one fourth the number of deliveries are performed each year, the center is not located in a poor inner city, there were fewer indigent patients, and the carriage rate for GBS was half that of ours. Boyer et al. 2 used universal antepartum culturing at 28 weeks' gestation, but then selectively administered intrapartum prophylaxis based on risk factors and culture results, and successfully eliminated GBS sepsis in their study population. A report from the University of Colorado 18 details a protocol of universal culturing and selective chemoprophylaxis in labor based on risk factors. This center is more similar to ours, serving an urban poor population, compliance with culturing at the specified time of 61% compared with our 56%, and 80.3% adherence to prophylaxis in labor according to the protocol. They, too, did not see a change in the overall neonatal sepsis rate from GBS and estimated that, even if the protocol was applied perfectly, 25% to 30% of all GBS cases would fail to be prevented, an estimate also made by the CDC. Additional reports of GBS surveillance programs in which favorable results were obtained also differed from our strategy. Mo- rales et al. 19 used a rapid screening technique, instead of traditional cultures, and the timing for their surveillance was at the time the patient presented in labor. Siegel et al. 20 describes successful neonatal chemoprophylaxis, rather than maternal, with decreased neonatal sepsis rates; no maternal surveillance culturing was performed. However, in all these studies, although a significant decrease in neonatal colonization with GBS was demonstrated and a decrease in neonatal sepsis was achieved, no significant decrease in neonatal mortality was documented. Inability to demonstrate decreased neonatal mortality is probably a result of inadequate size of the populations studied to detect such a decrease.
Our inability to identify at-risk mothers may in part be related to the timing of our cultures. GBS carriage is unpredictable; Boyer et al. 1 demonstrated that when cultures were performed at 28 weeks' gestation, only 67% of those with positive cultures had persistent carriage at delivery, whereas 7.4% with negative cultures at 28 weeks were positive in labor. Yancey et al. 21 achieved an 87% sensitivity, a 96% specificity, and an 87% positive predictive value of GBS cultures per- formed at 35 to 36 weeks' gestation in predicting colonization at the time of labor. The current recommendation of the CDC 10 and the American College of Obstetrics and Gynecology, 11 if a culturing strategy is chosen, is to perform the cultures at 35 to 37 weeks. The culturing technique in obtaining the specimen, as performed by the physician or nurse, may have large interobserver variation. Although all residents are instructed in proper culturing technique, we had no quality control on the performance of the cultures to assure that the vaginal and anorectal areas were swabbed. Our poor culturing compliance rate of only 56% of the registered patients is multifactorial, resulting from patient noncompliance with prenatal visits and physician error. Human error in failing to obtain the culture may be improved with resident education efforts, especially in the case of the less experienced residents, improved supervision of the outpatient clinics, and the improved culturing methods such as those used in our microbiology laboratory. Thus, we do not believe the lack of subculturing with selective broth media would have had a major impact on our results.
Major obstacles to a more successful GBS program include factors over which we have little control: patient attendance in clinic, the high-risk nature of our patient population, the large percentage of unregistered patients with no prenatal care, and the nature of our large tertiary center. Reliable support personnel, fail-proof computer information systems for patient and laboratory data, and medical record retrieval are all problematic at our center. With shrinking resources it is unlikely that major improvements in these factors will occur soon. These all contribute to the difficulty of the health care provider in adhering to the GBS policy, especially in carrying out proper antibiotic prophylaxis in labor. This failure is explained in part by patients presenting too late in labor to receive adequate prophylaxis, a common problem for patients with PPROM or advanced preterm labor. Also, some patients did not receive the indicated antibiotics due to lack of availability of patient information at delivery and error on the part of the medical staff. Even more revealing is that 40% and 45% of infants in both time periods, respectively, acquired earlyonset GBS sepsis in the absence of risk factors or positive cultures. This result emphasizes the fact that with or without our GBS policy it was not possible to identify almost one half of the infants who acquired early-onset GBS disease at this institution.
We are intrigued by our decrease in neonatal mortality, but believe, because we have made no impact on the rate of GBS sepsis and because of the poor compliance with the GBS policy, that it most likely represents a sporadic finding. To address the issue of neonatal mortality we performed a power calculation and determined that we would need at least 13,000 deliveries with no early-onset GBS sepsis mortalities under our GBS surveillance program, before this finding reaches statistical significance. We would need to continue our GBS policy unchanged, but this is not a feasible alternative because we have now adopted the 1996 CDC guidelines for GBS surveillance. Since that time, and after the close of this study, we have had another neonatal early-onset GBS sepsis mortality. Nevertheless, we can not arrive at a definite conclusion in the current work because of the lack of sufficient power to do so. Despite this, some might view the decrease in neonatal mortality as being clinically significant.
In light of the unproven advantage of universal GBS screening in an inner-city center, logistics and expense incurred, and the inability of the physicians and institution to adequately comply with the policy, we suggest that in a setting such as ours attempts at universal culturing might better be replaced by the nonscreening alternative described by the CDC 10 in conjunction with the American College of Obstetricians and Gynecologists 11 and the American Academy of Pediatrics.
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This approach uses only risk factors to select patients for GBS antibiotic prophylaxis. We believe this may be a better choice than universal screening; however, we caution against extrapolating the information presented in this report to populations not similar to our own. Antibiotic prophylaxis would be reserved, in this paradigm, for patients with proven risk factors for neonatal group B sepsis, including PTD, PPROM, PROM of Ͼ18 hours; chorioamnionitis; and a previously affected child with GBS disease. This approach is more rational and will likely achieve similar results, but with fewer problems than encountered in our attempts at a universal GBS screening policy. 
